InfertilitySEQ-ETNCT07499453
Impact of Sequential Double Embryo Transfer on Live Birth Rates: A Case-Control Study.
An observational study of Infertility, run by Hopital Pierre Rouques - Les Bluets at 1 site in France.
Trial summary
The main aim of this study is to evaluate the impact and identify potential indications for sequential double embryo transfer (SEQ-ET) in couples undergoing assisted reproductive technology (ART). Read more about this study
- Who is it for?
- Ages 20 to 42 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Infertility
- How many people
- 778 participants
- Where
- 1 siteFrance
- Study dates
- Jan 2014to Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 42 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: The study population consists of couples undergoing assisted reproductive technology (ART) at Pierre Rouquès - Les Bluets Hospital between January 2014 and December 2023. Female participants are biologically capable of becoming pregnant and have undergone either sequential double embryo transfer (SEQ-ET) or standard double embryo transfer (DET). The population includes women with a history of previous ART attempts, and does not exclude participants based on the presence or absence of a specific disease or condition.
Who may be able to join
- Infertile patients undergoing IVF with planned SEQ-ET or DET.
- Age ≤ 42 years.
Who cannot join
- Age aged 43 years.
- Cycles in which only a single embryo was ultimately transferred and cycles in which no embryo transfer occurred.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A CASE-CONTROL OBSERVATIONAL STUDY ON THE IMPACT OF A SEQUENTIAL DOUBLE EMBRYO TRANSFER POLICY ON LIVE BIRTH RATES IN COUPLES UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGY.
The main aim of this study is to evaluate the impact and identify potential indications for sequential double embryo transfer (SEQ-ET) in couples undergoing assisted reproductive technology (ART). The study will compare live birth rates (LBR) between patients receiving SEQ-ET and those receiving standard double embryo transfer (DET), while assessing safety outcomes and potential indications, including endometrial immune under-activation. Each SEQ-ET case will be matched with a DET control based on age, transfer attempt rank, and ART technique. We hypothesize that SEQ-ET may enhance implantation in couples with previous ART failures without increasing the risk of complications, potentially through localized maternal-endometrial immune communication initiated by the initially transferred cleavage-stage embryos.
- Conditions
- Infertility
- Keywords
- IVF, Sequential embryo transfer, Live birth rate
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Case group | Patients who underwent a SEQ-ET of one or two cleavage-stage embryos (day 2/3) followed by the transfer of a blastocyst-stage embryo (day 5/6) within the same cycle. | |
| Control group | Patient who underwent a simultaneous DET defined as the transfer of two blastocyst-stage embryos (day 5 or day 6) in the same cycle. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Live birth rate
LBR defined as delivery of a viable infant beyond 24 weeks of gestation, assessed after the first fresh or frozen blastocyst transfer.
Measured: From first embryo transfer to delivery (up to approximately 9 months).
Secondary outcomes (4)
Clinical Pregnancy Rate
Clinical pregnancy confirmed by ultrasound visualization of a gestational sac.
Measured: 6-8 weeks after embryo transfer.
Miscarriage Rate per Clinical Pregnancy
Pregnancy loss before 24 weeks of gestation among clinical pregnancies.
Measured: Up to 24 weeks of gestation.
Implantation Rate
Number of gestational sacs per number of embryos transferred.
Measured: 6-8 weeks after embryo transfer.
Multiple pregnancies
Percentage of multiple pregnancies regardless of whether one or two day-2/3 are transferred before the day-5 embryo are transferred.
Measured: Up to 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2026
- Study startJan 2014
- Primary completionDec 2023
- Study completionSep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 778 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hopital Pierre Rouques - Les Bluets
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07499453
- Sponsor's protocol ID
- SEQ-ET-2026
- Acronym
- SEQ-ET
- Status last verified
- Mar 2026
- First submitted
- 24 Mar 2026
- Last updated
- 30 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A CASE-CONTROL OBSERVATIONAL STUDY ON THE IMPACT OF A SEQUENTIAL DOUBLE EMBRYO TRANSFER POLICY ON LIVE BIRTH RATES IN COUPLES UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGY.
- ClinicalTrials.gov ID
- NCT07499453
- Acronym / sponsor ID
- SEQ-ET / SEQ-ET-2026
- Conditions
- Infertility
- Keywords
- IVF, Sequential embryo transfer, Live birth rate
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 778 participants (actual)
- Lead sponsor
- Hopital Pierre Rouques - Les BluetsUniversity, hospital or other
- Study start
- Jan 2014 (actual)
- Primary completion
- Dec 2023 (actual)
- Study completion
- Sep 2024 (actual)
- First posted
- 30 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main aim of this study is to evaluate the impact and identify potential indications for sequential double embryo transfer (SEQ-ET) in couples undergoing assisted reproductive technology (ART). The study will compare live birth rates (LBR) between patients receiving SEQ-ET and those receiving standard double embryo transfer (DET), while assessing safety outcomes and potential indications, including endometrial immune under-activation. Each SEQ-ET case will be matched with a DET control based on age, transfer attempt rank, and ART technique. We hypothesize that SEQ-ET may enhance implantation in couples with previous ART failures without increasing the risk of complications, potentially through localized maternal-endometrial immune communication initiated by the initially transferred cleavage-stage embryos.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Case group | – | –Patients who underwent a SEQ-ET of one or two cleavage-stage embryos (day 2/3) followed by the transfer of a blastocyst-stage embryo (day 5/6) within the same cycle. |
| Control group | – | –Patient who underwent a simultaneous DET defined as the transfer of two blastocyst-stage embryos (day 5 or day 6) in the same cycle. |
Who may qualify
- Ages
- 20 to 42 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- The study population consists of couples undergoing assisted reproductive technology (ART) at Pierre Rouquès - Les Bluets Hospital between January 2014 and December 2023. Female participants are biologically capable of becoming pregnant and have undergone either sequential double embryo transfer (SEQ-ET) or standard double embryo transfer (DET). The population includes women with a history of previous ART attempts, and does not exclude participants based on the presence or absence of a specific disease or condition.
Key inclusion criteria (2 listed)
- Infertile patients undergoing IVF with planned SEQ-ET or DET.
- Age ≤ 42 years.
Key exclusion criteria (2 listed)
- Age aged 43 years.
- Cycles in which only a single embryo was ultimately transferred and cycles in which no embryo transfer occurred.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Live birth rate
Time frame: From first embryo transfer to delivery (up to approximately 9 months).
LBR defined as delivery of a viable infant beyond 24 weeks of gestation, assessed after the first fresh or frozen blastocyst transfer.
4 secondary outcomes
Clinical Pregnancy Rate
Time frame: 6-8 weeks after embryo transfer.
Miscarriage Rate per Clinical Pregnancy
Time frame: Up to 24 weeks of gestation.
Implantation Rate
Time frame: 6-8 weeks after embryo transfer.
Multiple pregnancies
Time frame: Up to 9 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Infertility
RecruitingObservational study
International Pilot Study for Dual Non-invasive Assesment of Embryo Development
Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infertility, run by Hopital Pierre Rouques - Les Bluets at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Live birth rate (time frame: From first embryo transfer to delivery (up to approximately 9 months).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.